ISRG Quote, Financials, Valuation and Earnings

Insulet Corp. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 12.4%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Insulet Corp.'s return on equity of 18.92%.

Intuitive Surgical, Inc. has a consensus price target of $599.60, signalling upside risk potential of 3.86%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 32.3%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than Insulet Corp. quarterly revenues of $706.3M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than Insulet Corp.'s net income of $87.6M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 76.42x while Insulet Corp.'s PE ratio is 82.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.84x versus 8.19x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 14.18%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Stryker Corp.'s return on equity of 14.06%.

Intuitive Surgical, Inc. has a consensus price target of $599.60, signalling upside risk potential of 3.86%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.66%. Given that Stryker Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Stryker Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Intuitive Surgical, Inc.'s net income of $709.2M is lower than Stryker Corp.'s net income of $859M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 76.42x while Stryker Corp.'s PE ratio is 46.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.84x versus 5.62x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 17.41%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Intuitive Surgical, Inc. has a consensus price target of $599.60, signalling upside risk potential of 3.86%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 24.59%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 76.42x while West Pharmaceutical Services, Inc.'s PE ratio is 41.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.84x versus 6.70x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 11.55%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Intuitive Surgical, Inc. has a consensus price target of $599.60, signalling upside risk potential of 3.86%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.04 which suggests that it could grow by 14.1%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1.07% to investors and pays a quarterly dividend of $0.24 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Intuitive Surgical, Inc.'s net income of $709.2M is higher than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 76.42x while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.84x versus 2.22x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.